

ORIGINAL

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Grutzmann, et al.

Application No.: 10/019,007 Group No.: 1617

Filed: 12/21/2001 Examiner: Hui, San Ming. R.

For: Combination of MTP Inhibitors and HMG-CoA Reductase Inhibitors and the Use Thereof

in Medicaments

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: JAN 2 3 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT BEFORE MAILING DATE OF EITHER A FINAL ACTION OR NOTICE OF ALLOWANCE (37 C.F.R. § 1.97(c))

TIME OF TRANSMITTAL OF ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

- The information disclosure statement transmitted herewith is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but before the mailing date of either
 - (1) a final action under section 1.113 or
 - (2) a notice of allowance under section 1.311

whichever occurs first.

FEE

2. Accompanying this transmittal is the fee for submission of an information disclosure statement under § 1.97(c). (\$180.00)

FEE PAYMENT

3. Applicant elects the option to pay the fee set forth in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under § 1.97(c) (\$180.00).

Fee due \$ 180.00

METHOD OF PAYMENT OF FEE

4. Please charge Account No. 13-3372 in the amount of \$ 180.00. The Commissioner is also authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Reg. No. 31,018

Telephone: (203) 812-2712

Date: January 23, 2004

William F. Gray

Attorney for Applicant(s)

Bayer Corporation 400 Morgan Lane

West Haven, CT 06516

Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office	Serial No. 10/019,007	Group Art Unit 1617	Filing Date 12/21/2001	Atty. Docket No. Le A 33 846			
INFORMATION DISCLOSURE CITATION	Applicant(s) Grützmann, et al.						

	U.S. PATENT DOCUMENTS												
*		DOCUMENT NO.				DATE MM/DD/YY	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE			
						,							
								-					
										-			

FOREIGN PATENT DOCUMENTS														
				חחרו	IMEN	NT NO. DATE	DATE	COUNTRY	PRIMARY	SUB-	TRANSLATION			
			,		IVILLI	1110		,	DD/MM/YY	COOMIN	CLASS	CLASS	YES	NO
· :														
														L

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	R1	Schwartz, Stephen, M. et al., How does Diabetes Accelerate Atherosclerotic Plaque Rupture and Arterial Occlusion? Frontiers in Bioscience 8; s1371-1383; Sept. 1, 2003.					

EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.